FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
2037PDF: 537HTML: 306XML: 191 -
The key to fibrinolysis and thrombolysis
1700PDF: 527HTML: 263 -
CO018 | THE MOLI-SANI RISK SCORE, A MEASURE OF MODIFIABLE CARDIOVASCULAR RISK, PREDICTS NON-CARDIOVASCULAR MORTALITY AND SELECTED CANCERS, BUT NOT NEURODEGENERATIVE DISEASES F. Bracone1, S. Costanzo1|2, M. Bonaccio1, T. Panzera1, A. De Curtis1, S. Magnacca1, C. Cerletti1, MB. Donati1, G. de Gaetano1, L. Iacoviello1|3, A. Di Castelnuovo1 | 1Unità di Ricerca di Epidemiologia e Prevenzione, IRCCS Neuromed, Pozzilli, Italy; 2Università della Insubria, Varese, Italy; 3Università LUM Giuseppe Degennaro, Casamassima, Italy
30PDF: 9 -
CO-53 | LIVER FIBROSIS, STEATOSIS AND SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH HEMOPHILIA: A CROSS-SECTIONAL STUDY C. Simion1|2, B. Stocco1|2, I. Condonato1|2, E. Dalla Porta1|2, A. Napolitano1|2, E. Zanon1|2, L. Fabris1, L. Spiezia1|2, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
38PDF: 17 -
CO060 | LP(a) AND CARDIOVASCULAR RISK IN FAMILIAL HYPERCHOLESTEROLEMIA F. Basso1, G. Barbieri1, E. Sticchi1, A. Kura1, P. Cantini1, S. Suraci1, M. Berteotti1, E. Lotti1, F. Crudele1, G.M. Scaturro2, A. Rogolino1, A.M. Gori1, R. Marcucci1, B. Giusti1 | 1Atherothrombotic Diseases Center, Department of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, Firenze, Italy; 2Meyer Children's Hospital IRCCS, Metabolic and Neuromuscular Unit, Firenze, Italy
30PDF: 10 -
CO13 | Genetic background in hypercholesterolemic patients framing cardiovascular risk A. Kura1, E. Sticchi2, G. Barbieri1, R. Orsi1, S. Suraci1, G.M. Scaturro3, E. Lotti4, F. Crudele4, M. Berteotti2, A.M. Gori2, R. Marcucci2, B. Giusti2 | 1Department of Experimental and Clinical Medicine, Firenze; 2Department of Experimental and Clinical Medicine, Atherothrombotic Diseases Center, Careggi Hospital, Firenze; 3Meyer Children’s Hospital IRCCS, Firenze; 4Atherothrombotic Diseases Center, Careggi Hospital, Firenze, Italy
723PDF: 25 -
CO009 | EVALUATION OF A NON-LABORATORY CARDIOVASCULAR RISK SCORE ADAPTED FOR RURAL TANZANIA F. Mazzinghi1, B.S. Kakala1, J.J. Thomas1, R.J. Itambu1, B. Ndunguru1, S. Marwa1, B. Mfaume1, A. Mele1, M. Tilli1, E. Mwumbe1, P. Belardi1, G. Torelli2, M. Saugo3, P. Bartolotta3, V. Scheggi4, R. Marcucci5 | 1Doctors with Africa CUAMM, Iringa, Tanzania; 2Doctors with Africa CUAMM, Padova, Italy; 3Department of clinical and evaluative epidemiology, Trento Health Service, Trento, Italy; 4Cardiovascular Medicine, Careggi University Hospital, Firenze, Italy; 5Department of clinical and experimental medicine, University of Florence, Firenze, Italy
33PDF: 10 -
PO137 | SMAD3 VARIANTS IN LOEYS-DIETZ SYNDROME: RELATIONSHIP WITH NON-AORTIC CARDIOVASCULAR FEATURES E. Sticchi1, L. Squillantini1, P. Cantini1, S. Suraci1, F. Basso1, G. Barbieri1, A. Kura1, F. Gensini2, E. Fiorentini2, S. Nistri3, G. Pepe1, A.M. Gori1, M. Berteotti1, R. Marcucci1, B. Giusti1 | 1Atherothrombotic Diseases Center, Dpt. Experimental and Clinical Medicine, University of Florence - Careggi Hospital, Firenze, Italy; 2Dpt. Experimental and Clinical Biomedical Sciences 'Mario Serio', Medical Genetics Unit, University of Florence, Firenze, Italy; 3Cardiology Service CMSR Veneto Medica Altavilla Vicentina, Vicenza, Italy
26PDF: 10 -
Platelet distribution width is associated with cardiovascular mortality in an adult general population
3088PDF: 515Supplementary Material: 144 -
PO144 | KIV2 LPA POLYMORPHISM: ROLE IN BAV CLINICAL COMPLICATIONS ACCORDING TO DIFFERENT CLINICAL SETTINGS P. Cantini1, E. Sticchi1, G. Barbieri1, R. Orsi1, A. Kura1, F. Basso1, A. Rogolino1, M. Berteotti1, S. Nistri2, P. Stefàno3, R. Marcucci1, B. Giusti1 | 1Atherothrombotic Diseases Center, Dep. of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, Firenze, Italy; 2Cardiology Service CMSR Veneto Medica Altavilla Vicentina, Vicenza, Italy; 3Cardiac Surgery Unit, Department of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, Firenze, Italy
22PDF: 9 -
PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi1, C. Tamburini2, M. Littera2, M. Mazzetti2 | 1SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; 2SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
26PDF: 7 -
CO47 | Genetic characterization of the KIV2 LPA polymorphism in subjects with bicuspid aortic valve with different clinical complications R. Orsi1, G. Barbieri1, E. Sticchi1,2, A. Kura1, L. Squillantini1, P. Cantini1, A. Rogolino2, M. Berteotti1,2, S. Nistri3, P. Stefàno4, R. Marcucci1,2, B. Giusti1,2 | 1Department of Experimental and Clinical Medicine, University of Firenze; 2Centre for Atherothrombotic Diseases, AOU Careggi, Firenze; 3Cardiology, CMSR Veneto Medica, Altavilla Vicentina; 4Cardiac Surgery, AOU-Careggi, Firenze, Italy
622PDF: 16 -
PO032 | INHIBITION OF PLATELET ACTIVATION BY SMALL MOLECULE SYNTHETIC AGONISTS OF THE BILE ACID RECEPTOR: A NOVEL APPROACH TO ANTIPLATELET THERAPY L. Bury1, E. Falcinelli1, V. Fazzi1, C. Tili1, P. Gresele1, S. Fiorucci2 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine; 2Section of Gastroenterology, University of Perugia, Italy
22PDF: 9 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
443PDF: 92 -
CO26 | Relationship between SMAD3 variants and non-aortic cardiovascular features L. Squillantini, E. Sticchi, P. Cantini, S. Suraci, A. Rogolino, F. Gensini, S. Nistri, G. Pepe, A.M. Gori, M. Berteotti, R. Marcucci, B. Giusti | Università degli Studi di Firenze, Dipartimento di Medicina Sperimentale e Clinica, Firenze, Italy
590PDF: 18 -
CO10 | Multidimensional risk assessment of venous thromboembolism: an observational study comparing the Padua prediction score, Barthel index, and quality of life in hospitalized patients A. Mameli, S. Cornacchini, P. Schirru, F. Marongiu, D. Barcellona | Hemostasis and Thrombosis Unit, University of Cagliari, Italy
692PDF: 27 -
CO27 | Intracerebral hemorrhage in hemophilia A and B: a 10-year prospective multicenter study in Italy (2012–2022) E. Zanon1, A. Napolitano1, A. Porreca2, F. Demartis3, A. Coppola4, C. Santoro5, I. Cantori6, A. C. Molinari7, C. Biasioli8, M. Luciani9, G. Sottilotta10, B. Pollio11, A. Borchiellini12, A. Tosetto13, P. Flora14, P. Simioni1 | 1Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua; 2Department of Human Sciences and Promotion of the Quality of Life, Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele Roma Open University, Roma; Unit of Clinical and Molecular Epidemiology IRCCS San Raffaele, Roma; 3Centre for Bleeding Disorders, Careggi University Hospital of Firenze; 4Azienda Ospedaliero Universitaria di Parma; 5Hematology Division, Umberto I University Hospital of Roma; 6Haemophilia Center, Department of Transfusion Medicine, Hospital of Macerata; 7IRCCS Istituto Giannina Gaslini, Genova; 8Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena; 9Children’s Hospital Bambino Gesù, Roma; 10Haemophilia Center, Department of Onco-Hematology and Radioterapy, Hospital of Reggio Calabria; 11Haemophilia Pediatric Center, Transfusion Medicine, City of Health and Science of Turin; 12City of Health and Science of Turin; 13Hemorrhagic and Thrombotic Diseases Unit, S. Bortolo Hospital of Vicenza; 14RCCS Foundation Ca’ Granda Maggiore Policlinico Hospital, Milan, Italy
692PDF: 31 -
PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy
558PDF: 22 -
CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY L. Girardi1|2, W. Ageno3, L. Bertù1, C. Lodigiani4, L.A. Ciuffini4, M.C. Vedovati5, C. Becattini5, A. Sammarco6, G. Camporese6, G. Cuni1|7, C. Ambaglio7, M.P. Donadini1 | 1Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, Varese, Italy; 2Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; 3Department of Medicine, University of Padua, Padova, Italy; 4Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 5Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; 6Clinica Medica 1, Department of Medicine, DIMED, Padova University Hospital, Padova, Italy; 7Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
35PDF: 9 -
CO059 | EXTRACELLULAR VESICLES AS BIOMARKERS IN FAMILIAL HYPERCHOLESTEROLEMIAS TREATED WITH EVINACUMAB C. Samà1, A. Benetti1, M.G. Lupo2, M. Biolo1, C. Portinari1, S. Zambon1, A. Zambon1, N. Ferri2, C.M. Radu1, P. Simioni1 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Padova, Italy; 2Department of Medicine, Padova University Hospital, Padova, Italy
21PDF: 10 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
759PDF: 26 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
749PDF: 21 -
CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis G. Gagliardi, E. Campello, A. Napolitano, B. Stocco, C. Di Gesù, G. Gobbo, I. Condonato, M. Allegra, G. Camporese, P. Scarinzi, R. Pesavento, F. Bilora, C. Bulato, A. Benetti, C. Samà, C. Portinari, G. Antonello, C. Goffi, L. Di Daniel, A. Zambon, L. Fabris, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
824PDF: 20 -
CO050 | INTERACTION BETWEEN DIRECT ORAL ANTICOAGULANTS AND ANTIEPILEPTIC DRUGS: A MULTICENTER OBSERVATIONAL STUDY A. Lipari1, S. Sorrentino1, M. De Siati1, L. D'Innocenzo1, A. Ferretti1, D. Menichelli2, V. Cammisotto2, P. Pignatelli2, G. Ragna3, MC. Vedovati3, C. Becattini3, G. Frisullo4, V. Forte5, T. Pirozzi1, L. Di Gennaro1, M. Basso1, E. De Candia1 | 1Unit of Haemostasis and Thrombosis Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Roma, Italy; 3Department of Internal and Cardiovascular Medicine and Stroke Unit, University of Perugia, Perugia, Italy; 4Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 5Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Roma, Italy
31PDF: 13 -
Clinical characteristics, prescription patterns and clinical outcomes of patients with extended therapy with direct oral anticoagulants for unprovoked venous thromboembolism Insights from the RIETE Registry
1573PDF: 139SUPPLEMENTARY FILES: 100APPENDIX: 120 -
CO03 | Early discharge and home treatment of low-risk pulmonary embolism: a cohort study E. Ruggeri1, L. Vulcano1, W. Ageno2, F. Cortellaro3, M.P. Donadini3,4 | 1Scuola di Medicina, Università degli Studi dell’Insubria, Varese; 2Dipartimento di Medicina, Università degli Studi di Padova; 3Pronto Soccorso e Medicina d’Urgenza, Ospedale di Circolo, ASST Sette Laghi, Varese; 4Dipartimento di Medicina e Chirurgia, Università degli Studi dell’Insubria, Varese, Italy
672PDF: 25 -
PO017 | BEYOND IONIC STRENGTH: ANION EFFECTS ON FIBRIN CLOT FORMATION, STRUCTURE, AND MECHANICAL PROPERTIES C. Spoliti1, T. Feller2, F.L. Macrae2, R.A.S. Ariëns2, R. De Cristofaro1|3, E. Di Stasio4|5 | 1Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Roma, Italy; 2Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom; 3Hemorrhagic and Thrombotic Diseases Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; 4Department of Basic Biotechnological Sciences, Intensive Care and Perioperative Clinics, Università Cattolica del Sacro Cuore, Roma, Italy; 5Clinical Chemistry, Biochemistry and Molecular Biology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
25PDF: 8 -
PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 I.C. Moschonas, A.D. Tselepis | Atherothrombosis Research Centre, University of Ioannina, Greece
484PDF: 98 -
PO145 | KINETIC ASSESSMENT OF PLATELET REACTIVITY DURING DUAL ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES: PRELIMINARY RESULTS FROM AN ONGOING STUDY B. Di Marco1|2, R. Liani1, F. D’Ambrosio1|2, M. Alfonsetti1, P.G. Simeone1, M. Frezza1, S. Porro1, M. Brambilla3, P. Lanuti1, M. Camera3, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti, Chieti, Italy; 2ASL 2 Abruzzo, SS. Annunziata Hospital, Chieti, Italy; 3Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino IRCCS, Milano, Italy
24PDF: 6 -
CO035 | THE ROLE OF INFLAMMATORY BIOMARKERS IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA F. Schieppati1|2, S. Bolognini1|2, C. Ticozzi1, O.C. Cretu1, P. Gomez-Rosas1|3, M. D’Adda4, V. Cancelli4, C. Ambaglio1, E. Galimberti1, L. Barcella1, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Hematology, Hospital Spedali Civili di Brescia, Brescia, Italy
28PDF: 10 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
440PDF: 90 -
CO02 | Hepatic fibrosis as predictor of cancer-associated thrombosis in patients with intrahepatic cholangiocarcinoma Y. Frion-Herrera1,2, C. Venturin1,3, M. Cadamuro4, J. Gasparello5, C.M. Radu1, M. Fassan5, C. Mescoli6, U. Cillo7, E. Gringeri7, G. Zanus8, L. Fabris1,3, P. Simioni1 | 1Clinical Medicine and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital, Department of Medicine [DIMED], University of Padua, Italy; 2Department of Biology [DiBio], University of Padua, Italy; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Department of Pathology Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Italy; 6Pathology Unit, Padua University-Hospital, Padua, Italy; 7Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy; 8General Surgery Unit, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy
719PDF: 26 -
CO071 | ATRIAL FIBRILLATION, CEREBRAL SMALL VESSEL DISEASE, AND GENDER MEDICINE: FOCUS ON BIOMARKERS AND NEUROIMAGING F. Alfano1|2, M. Berteotti1|2, F. Cesari1|2, AM. Gori1|2, E. Salvadori1, B. Giusti1|2, A. Bertelli1|2, L. Bicchi1|2, F. Fratini3, B. Formelli3, G. Salti3, E. Fainardi1|4, A. Ginestroni1|4, S. Chiti5, A. Poggesi1|3, R. Marcucci1|2 | 1Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy; 2Center for Atherothrombotic Diseases, Careggi University Hospital, Firenze, Italy; 3NEUROFARBA Department, Neuroscience Section, University of Florence, Firenze, Italy; 4Neuroradiology Unit, Careggi University Hospital, Firenze, Italy; 5Health Physics Unit, Careggi University Hospital, Firenze, Italy
39PDF: 17 -
CO098 | ANTI-β2GPI AND ANTI-PS/PT ANTIBODIES, AND THEIR COMBINATION, EXERT A DISTINCT PLATELET ACTIVATION PROFILE M. Camera1|2, A. Becchetti2, M.O. Borghi3|4, M. Brambilla2, P.A. Lonati4, C. Bodio4, E. Pontara5, M.G. Cattini5, E. Bison5, M. Tonello6, N. Pozzi7, P. Meroni4, V. Pengo5 | 1Department of Pharmaceutical Sciences, University of Milano, Milano, Italy; 2Unit of Cell and Molecular Biology in Cardiovascular Diseases, Centro Cardiologico Monzino IRCCS, Milano, Italy; 3Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milano, Milano, Italy; 4IRCCS Istituto Auxologico Italiano, Milano, Italy; 5Department of Cardiac-Thoracic-Vascular Sciences and Public Health, University of Padua, Padova, Italy; 6Department of Medicine, University of Padua, Padova, Italy; 7Saint Louis University School of Medicine, St. Louis, United States
32PDF: 9 -
CO007 | TPO-RECEPTOR AGONISTS AS AN INDEPENDENT RISK FACTOR FOR VENOUS THROMBOTIC EVENT IN IMMUNE THROMBOCYTOPENIA PATIENTS WITH PERSISTENT ANTIPHOSPHOLIPID ANTIBODIES POSITIVITY M. Biglietto, B. Mandelli, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, S. Truglia, C. Santoro | Sapienza, University of Rome, Italy
41PDF: 7 -
CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study Chiara Cavallaro1,2, Paolo Santini1,2, Laura Leoni3, Carolina Mosoni1,2, Silvia D’Ambrosio1,2, Francesco Mancinetti1,2, Nicola Coletta1,2, Michela Iorio1,2, Angelo Porfidia1,2, Alessandro D’Errico1,2, Rosa Talerico1,2, Roberto Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; 2Università Cattolica del Sacro Cuore, Rome; 3Vita-Salute University, San Raffaele Hospital IRCCS, Milan, Italy
673PDF: 29 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
626PDF: 20 -
CO-88 | TRANSIENT IDIOPHATIC ACQUIRED VON WILLEBRAND DISEASE: A RARE, CHALLENGING CONDITION WITH A POSSIBLE RAPID AND FAVORABLE EVOLUTION G. Murante1|2|3, S. Bergonzi1|2|3, M. Capetta1|2|3, F. Valeri1|2, C. Dainese1|2, A. Valpreda4, R. Pastorino1|3, F. Bocchi1|3, B. Bruno2|3, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza of Turin, Italy; 2Division of Hematology, AOU Città della Salute e della Scienza, University of Turin, Italy; 3Dep. of Molecular Biotechnology and Health Sciences, University of Turin, Italy; 4Central Lab. Baldi and Riberi, AOU Città della Salute e della Scienza of Turin, Italy
41PDF: 20 -
PO134 | FAMILIAL HYPERCHOLESTEROLEMIA 57-GENE PANEL MUTATIONAL ANALYSIS: INSIGHT INTO CARDIOVASCULAR RISK GENETIC PREDISPOSITION A. Kura1, E. Sticchi1, G. Barbieri1, F. Basso1, P. Cantini1, S. Suraci1, M. Berteotti1, E. Lotti1, F. Crudele1, G.M. Scaturro2, A. Rogolino1, A.M. Gori1, R. Marcucci1, B. Giusti1 | 1Atherothrombotic Diseases Center, Department of Experimental and Clinical Medicine, University of Florence - Careggi Hospital, Firenze, Italy; 2Meyer Children's Hospital IRCCS, Metabolic and Neuromuscular Unit, Firenze, Italy
28PDF: 7 -
CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin M. Sartori, A. Trentini, S. Cavara, L. Borgese, M. Soldati, B. Cosmi | Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
681PDF: 27 -
CO083 | IN VITRO CORRECTION OF SEVERE FACTOR V DEFICIENCY USING A NOVEL PLASMA-DERIVED FV CONCENTRATE: A WHOLE BLOOD THROMBIN GENERATION STUDY C. Bulato1, L. Spiezia1, E. Campello1, B. Serena1, S. Toffanin1, C. Simion1, A. Caricasole2, M. Sotgiu2, A. Salvatore2, F. Pierantoni2, T.M. Hackeng3|4, H.M.H. Spronk3|4, P. Simioni1 | 1Thrombotic and Hemorrhagic Diseases Unit, General Internal Medicine, Department of Medicine, Padova University Hospital, Italy; 2Kedrion SpA, Barga Lucca, Italy; 3Coagulation Profile B.V., Maastricht, the Netherlands; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, the Netherlands
20PDF: 10 -
CO-69 | IN VITRO CORRECTION OF SEVERE FACTOR V DEFICIENCY USING A NOVEL PLASMA-DERIVED FACTOR V CONCENTRATE: A WHOLE BLOOD THROMBIN GENERATION STUDY C. Bulato1, E. Campello1, L. Spiezia1, B. Serena1, S. Toffanin1, C. Simion1, A. Caricasole2, M. Sotgiu2, A. Salvatore2, F. Pierantoni2, T.M. Hackeng3|4, H.M.H. Spronk3|4, P. Simioni1 | 1First Chair of Internal Medicine, Thrombotic and Haemorrhagic Diseases Unit and Haemophilia Centre, Department of Medicine, Padova University Hospital, Padova, Italy; 2Kedrion SpA, Barga Lucca, Italy; 3Coagulation Profile B.V., Maastricht, Netherland; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherland
40PDF: 12 -
CO12 | Left internal carotid artery thrombosis in a patient with antiphospholipid antibody syndrome successfully treated with eculizumab A. Hoxha1, L. Nico2, F. Viaro3, L. Fabris1, Y.F. Herrera1, M. Munari4, C. Baracchini3, F. Causin2, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED, University of Padua; 2Neuradiology Unit, University Hospital of Padua; 3Stroke Unit, Neurology Department, University of Padua; 4Intensive Care Unit, University Hospital of Padua, Italy
683PDF: 21 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
763PDF: 22 -
CO021 | TIME COURSE OF LP(a) LEVELS AFTER ACUTE CORONARY SYNDROME: A LONGITUDINAL STUDY G. Barbieri1, A.M. Gori1, G. Ciarrocca Taranta1, M. Di Gioia1, F. Alfano1, E. Lotti1, A. Rogolino1, F. Cesari1, B. Giusti1, M. Berteotti1, R. Marcucci1 | 1Atherothrombotic Diseases Center, Department of Experimental and Clinical Medicine, University of Florence - Careggi Hospital, Firenze, Italy
36PDF: 11 -
CO-63 | ACQUIRED VON WILLEBRAND SYNDROME IN AN ELDERLY PATIENT WITH EARLY-STAGE B-CLL A. Casson1, I. Ricca1, A. Barchieri1, G. Guido1, P. Ocello1, M. Tucciarone1, S. Prestigio2, A. Alfano2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Italy; 2SC Laboratorio Analisi ASL TO4, Ivrea, Italy
42PDF: 18 -
CO11 | Oral anticoagulation with vitamin K antagonists in early childhood: a single centre-experience B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
712PDF: 25 -
PO047 | TRANSIENT IDIOPHATIC ACQUIRED VON WILLEBRAND SYNDROME: A RARE CHALLENGING CONDITION WITH A POSSIBLE RAPIDLY AND FAVOURABLE EVOLUTION G. Murante1|2|4, S. Bergonzi1|2|4, M. Capetta1|2|4, F. Valeri1|2, C. Dainese1|2, A. Valpreda3, R. Pastorino1|4, F. Bocchi1|4, B. Bruno2|4, A. Borchiellini1|2 | 1Regional Centre for Hemorrhagic and Thrombotic Diseases; 2Division of Hematology; 3Central Lab. Baldi and Riberi, AOU Città della Salute e della Scienza di Torino, Italy; 4Dep. of Molecular Biotechnology and Health Sciences, University of Turin, Italy
25PDF: 10
1 - 62 of 62 items
